Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 4248 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Novelos lung cancer drug posts good results

Forty-four late-stage lung cancer patients who had not received prior chemotherapy were randomized to one of three groups for six months of treatment with the drug. The study

Isis extends drug discovery partnership with Lilly

Isis and Lilly will continue to advance antisense drugs identified during the previous collaboration, and continue their efforts to develop and refine antisense technologies. During the extension, Isis

BioFocus and Organon extend collaboration

BioFocus, a UK biotechnology company, will receive undisclosed fees from Organon for its role in the collaboration. The agreement is the second part of the company’s agreement with

Merck KGaA sets up US generic drugs business

“This will increase Merck’s presence in the world’s largest pharmaceutical market and will help solidify our position as the world’s third-largest global generics company,” said Hank Klakurka, CEO